Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions

Division

West Florida

Hospital

Largo Medical Center

Document Type

Case Report

Publication Date

1-1-2025

Keywords

Hidradenitis Suppurativa, Humans, Interleukin-17, Antibodies, Monoclonal, Humanized, Quality of Life

Disciplines

Dermatology | Medicine and Health Sciences | Skin and Connective Tissue Diseases

Abstract

Hidradenitis suppurativa (HS) is a debilitating dermatologic disorder characterized by recurrent inflammation that affects the apocrine glands and hair follicles and profoundly impacts patients' quality of life. Current treatment strategies ranging from topical therapies to systemic biologics aim to alleviate symptoms and prevent disease progression. Bimekizumab, an IL-17A and IL-17F inhibitor, has emerged as a promising intervention in the HS treatment landscape. We present a comprehensive review of the underlying molecular pathophysiology of HS, current standards of care, and evaluation of the efficacy and safety of bimekizumab.

Publisher or Conference

Cutis

Link to Full Text

Share

COinS